Valuation: Evotec SE

Capitalization 100.25Cr 118.35Cr 92Cr 87Cr 161.79Cr 11TCr 164.63Cr 1.08TCr 423.6Cr 5.31TCr 443.93Cr 434.7Cr 19TCr P/E ratio 2026 *
-9.6x
P/E ratio 2027 * -23.3x
Enterprise value 102.08Cr 120.5Cr 94Cr 89Cr 164.74Cr 11TCr 167.63Cr 1.1TCr 431.32Cr 5.41TCr 452.02Cr 442.62Cr 19TCr EV / Sales 2026 *
1.35x
EV / Sales 2027 * 1.27x
Free-Float
88.77%
Yield 2026 *
-
Yield 2027 * -
1 day-2.43%
1 week+16.06%
Current month+27.16%
1 month+26.95%
3 months-7.51%
6 months-18.51%
Current year+0.09%
1 week 4.84
Extreme 4.836
5.76
1 month 4.01
Extreme 4.01
5.76
Current year 4
Extreme 3.995
6.73
1 year 4
Extreme 3.995
8.57
3 years 4
Extreme 3.995
24.44
5 years 4
Extreme 3.995
45.83
10 years 3.1
Extreme 3.1
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 50 01/03/2025
Chief Tech/Sci/R&D Officer 62 01/09/2010
Director TitleAgeSince
Chairman 65 15/06/2021
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Change 5d. change 1-year change 3-years change Capi.($)
-2.48%+16.06%-20.18%-68.64% 118.35Cr
-2.34%+2.48%-3.53%-6.95% 4.87TCr
-1.68%+3.49%+37.99%+22.48% 3.59TCr
+0.65%+10.17%+310.71%+514.63% 3.13TCr
-0.72%+3.91%+37.10%+33.05% 2.98TCr
+0.05%+1.33%+23.41%-12.24% 2.96TCr
+0.40%-1.03%+52.65%+196.30% 1.51TCr
+0.51%+3.35%+79.24%+175.14% 1.49TCr
-0.60%+6.96%+40.67%+15.39% 1.45TCr
-1.08%-11.31%+3,646.72%+3,908.27% 1.42TCr
Average -0.75%+11.65%+420.48%+477.74% 2.35TCr
Weighted average by Cap. -0.84%+11.65%+284.74%+333.03%

Financials

2026 *2027 *
Net sales 76Cr 89Cr 70Cr 66Cr 122.12Cr 8.27TCr 124.26Cr 815.39Cr 319.72Cr 4.01TCr 335.07Cr 328.1Cr 14TCr 83Cr 98Cr 77Cr 73Cr 134.46Cr 9.1TCr 136.83Cr 897.83Cr 352.05Cr 4.41TCr 368.95Cr 361.27Cr 16TCr
Net income -9.7Cr -11Cr -8.93Cr -8.45Cr -16Cr -1.06TCr -16Cr -104.54Cr -41Cr -513.69Cr -43Cr -42Cr -1.81TCr -3.19Cr -3.77Cr -2.94Cr -2.78Cr -5.15Cr -348.57Cr -5.24Cr -34Cr -13Cr -168.97Cr -14Cr -14Cr -595.53Cr
Net Debt 1.83Cr 2.16Cr 1.68Cr 1.59Cr 2.95Cr 199.53Cr 3Cr 20Cr 7.72Cr 97Cr 8.09Cr 7.92Cr 340.9Cr 5.88Cr 6.94Cr 5.41Cr 5.12Cr 9.48Cr 641.93Cr 9.65Cr 63Cr 25Cr 311.17Cr 26Cr 25Cr 1.1TCr
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,467
Date Price Change Volume
20/26/20 5.455 -3.28% 5,86,936
17/26/17 5.640 +1.26% 7,52,364
16/26/16 5.570 +0.45% 6,71,000
15/26/15 5.545 +2.88% 11,84,261
14/26/14 5.390 +14.68% 16,03,462
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
5.640EUR
Average target price
6.833EUR
Spread / Average Target
+21.16%

Quarterly revenue - Rate of surprise